pravastatin has been researched along with gemfibrozil in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.85) | 18.7374 |
| 1990's | 22 (42.31) | 18.2507 |
| 2000's | 19 (36.54) | 29.6817 |
| 2010's | 9 (17.31) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Fent, K; Popovic, M; Smital, T; Zaja, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ambrosio, G; Chiariello, M; Lepore, S; Napoli, C | 1 |
| Altomare, S; Citella, C; Colombo, L; Craveri, A; Giavardi, L; Lanfredini, M; Pedrazzini, L; Picollo, S; Vignati, A | 1 |
| Arca, M; Avellone, G; Avogaro, P; Baggio, G; Bittolo Bon, G; Bompiani, GD; Capurso, A; Cattin, L; Crepaldi, G; D'Alŏ, G | 1 |
| Dammann, HG; Ditschuneit, H; Ditschuneit, HH; Dreyer, M | 1 |
| Chiesa, G; Franceschini, G; Gianfranceschi, G; Sirtori, CR; Sirtori, M; Vaccarino, V | 1 |
| Brown, WV; Karmally, W; Smith, DA | 1 |
| Miettinen, TA; Vanhanen, HT | 1 |
| Faergeman, O; Gerdes, LU; Hansen, PS; Klausen, IC; Meinertz, H | 1 |
| Tobert, JA | 2 |
| Gibson, CM; Pasternak, RC; Rosner, B; Sacks, FM; Stone, PH | 1 |
| Frauenheim, WA; Rosenson, RS | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Angelin, B; Berglund, L; Bergman, M; Bondjers, G; Carlsson, A; Lindén, T; Miettinen, T; Odman, B; Olofsson, SO; Wiklund, O | 1 |
| Giraldez, RR; Mansur, AP; Maranhão, RC; Pileggi, F; Ramires, JA; Safi Júnior, J; Santos, RD | 1 |
| Bondjers, G; Camejo, G; Wiklund, O; Wright, I | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA | 1 |
| Abe, K; Goto, D; Kuwano, M; Okimoto, T; Ono, M; Shimotsu, H; Tsujita, Y | 1 |
| Sinzinger, H | 1 |
| Iliadis, EA; Rosenson, RS | 1 |
| Avramopoulos, A; Kounis, N; Kouskoukis, K; Pispirigos, K; Simopoulos, K | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Durrington, P | 1 |
| Plutzky, J; Ridker, PM | 1 |
| Dunlay, R; Koch, M; Lund, RJ; Meares, AJ; Oldemeyer, JB | 1 |
| Athyros, VG; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Mikhailidis, DP; Milionis, HJ; Rizos, E | 1 |
| Alaupovic, P; Collet, JP; Harvey, L; Leiter, L; McQueen, MJ; Schweitzer, M; Tessier, D; Vlahos, WD | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Backman, JT; Kyrklund, C; Neuvonen, M; Neuvonen, PJ | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Nakagomi-Hagihara, R; Nakai, D; Tokui, T | 1 |
| Brun, ME; Funk, C; Noé, J; Portmann, R | 1 |
| Abe, T; Ikeda, T; Nakagomi-Hagihara, R; Nakai, D; Tokui, T | 1 |
| Doncheva, NI; Nikolov, KV; Vassileva, DP | 1 |
| Gratsianskii, NA; Vaulin, NA | 1 |
| Dimitri, E; Landry, P; Légaré, N; Tessier, S | 1 |
| Bergin, C; Moriarty, M; Nolan, DP; O'Connor, C; O'Connor, MB; O'Leary, A | 1 |
| Bergman, A; Feng, B; Goosen, TC; Lai, Y; Litchfield, J; Varma, MV | 1 |
| Chen, EC; Chen, Y; Choo, EF; Liu, L; Ma, F; Mao, J; Sahasranaman, S; Zhu, R | 1 |
| Bauer, I; Herminghaus, A; Laser, E; Picker, O; Schulz, J; Truse, R; Vollmer, C | 1 |
6 review(s) available for pravastatin and gemfibrozil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pravastatin | 1992 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
Smoking diminishes the beneficial effect of statins: observations from the landmark trials.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Gemfibrozil; Humans; Lovastatin; Myocardial Ischemia; Pravastatin; Risk Factors; Simvastatin; Smoking | 2001 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
20 trial(s) available for pravastatin and gemfibrozil
| Article | Year |
|---|---|
[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pravastatin | 1992 |
[Changes in lipid status during pravastatin treatment].
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Gemfibrozil; Humans; Hypercholesterolemia; Lipids; Middle Aged; Pravastatin; Time Factors; Triglycerides | 1992 |
Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Italy; Male; Middle Aged; Naphthalenes; Pravastatin; Triglycerides | 1991 |
[Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Female; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Naphthalenes; Pravastatin; Triglycerides | 1991 |
Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
Topics: Apolipoproteins; Cholesterol; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Naphthalenes; Pravastatin; Time Factors; Triglycerides | 1989 |
Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination.
Topics: Absorption; Apolipoproteins; Cholestanol; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Lipoproteins; Male; Middle Aged; Pravastatin; Squalene; Sterols; Triglycerides | 1995 |
Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study.
Topics: Adult; Apolipoprotein B-100; Apolipoproteins B; Cross-Over Studies; Female; Gemfibrozil; Heterozygote; Humans; Male; Middle Aged; Mutation; Pravastatin; Statistics as Topic | 1994 |
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
Topics: Anticholesteremic Agents; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Gemfibrozil; Humans; Lipids; Male; Middle Aged; Niacin; Pravastatin; Treatment Outcome | 1994 |
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.
Topics: Adult; Aged; Analysis of Variance; Apolipoproteins B; Cholesterol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Single-Blind Method | 1993 |
[Comparative study of gemfibrozil versus pravastatin in the treatment of patients with coronary artery disease and low HDL cholesterol levels].
Topics: Analysis of Variance; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Middle Aged; Pravastatin | 1995 |
Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs.
Topics: Adult; Aged; Anticholesteremic Agents; Arteries; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Proteoglycans | 1996 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Creatine; Creatine Kinase; Drug Therapy, Combination; Female; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver Function Tests; Male; Middle Aged; Pravastatin; Retrospective Studies; Safety; Treatment Outcome; Triglycerides | 1999 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Simvastatin; Stroke | 2001 |
A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Apolipoproteins; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Evaluation; Female; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Patient Compliance; Phenotype; Pravastatin; Treatment Outcome; Triglycerides | 2002 |
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2002 |
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.
Topics: Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Interactions; Female; Gemfibrozil; Half-Life; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Male; Pravastatin | 2003 |
Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia.
Topics: Dyslipidemias; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2006 |
Use of lipid-modulating drugs in complicated course of coronary heart disease.
Topics: Antithrombin III; Atorvastatin; Cholesterol, LDL; Coronary Disease; Echocardiography; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Peptide Hydrolases; Pravastatin; Prothrombin; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
27 other study(ies) available for pravastatin and gemfibrozil
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
Topics: Animals; Evolution, Molecular; Glycosylation; Gonadal Steroid Hormones; HEK293 Cells; Humans; Ion Transport; Organic Anion Transporters; Protein Multimerization; Zebrafish; Zebrafish Proteins | 2013 |
Treating hyperlipidemia, Part III: Drug therapy.
Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Pravastatin | 1987 |
HMG-CoA reductase inhibitors, gemfibrozil, and myopathy.
Topics: Drug Combinations; Drug Interactions; Follow-Up Studies; Gemfibrozil; Humans; Lovastatin; Muscular Diseases; Pravastatin | 1995 |
Safety of combined pravastatin-gemfibrozil therapy.
Topics: Cholesterol, LDL; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; Pravastatin | 1994 |
Lovastatin and myopathy.
Topics: Drug Synergism; Gemfibrozil; Humans; Lovastatin; Muscular Diseases; Pravastatin | 1994 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts.
Topics: Carcinoma, Hepatocellular; Dactinomycin; ErbB Receptors; Gemfibrozil; Gene Expression Regulation, Neoplastic; Genes, Reporter; Half-Life; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Neoplasms; Mevalonic Acid; Neoplasm Proteins; Pravastatin; Promoter Regions, Genetic; Receptors, LDL; RNA, Messenger; RNA, Neoplasm; Transfection; Tumor Cells, Cultured; Up-Regulation | 1997 |
Evaluation of kidney and liver subacute toxicity induced by Bezalip-Pravastatin-Lopid antihyperlipidaemic compounds in rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Antihypertensive Agents; Aspartate Aminotransferases; Bezafibrate; Enzyme Inhibitors; gamma-Glutamyltransferase; Gemfibrozil; Hydroxymethylglutaryl CoA Reductases; Kidney; Liver; Male; Pravastatin; Rats; Rats, Wistar | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
A case for lipid-lowering?
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides | 2000 |
Statins for stroke: the second story?
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pravastatin; Risk Factors; Simvastatin; Stroke | 2001 |
Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Topics: Acute Kidney Injury; Aged; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Rhabdomyolysis; Simvastatin | 2000 |
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Pravastatin; Treatment Outcome | 1999 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans.
Topics: Animals; Anticholesteremic Agents; Cell Line, Transformed; Dose-Response Relationship, Drug; Drug Antagonism; Gemfibrozil; Humans; Kidney; Mice; Mice, Transgenic; Organic Anion Transporters, Sodium-Independent; Pravastatin | 2007 |
Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Topics: Animals; Anticholesteremic Agents; Biological Transport; Cell Line; CHO Cells; Chromans; Cricetinae; Cricetulus; Drug Interactions; Estrone; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Hepatocytes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Indoles; Kinetics; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pravastatin; Protein Binding; Recombinant Proteins; Simvastatin; Solute Carrier Organic Anion Transporter Family Member 1B3; Taurocholic Acid; Thiazolidinediones; Troglitazone | 2007 |
Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1.
Topics: Animals; Anticholesteremic Agents; Drug Interactions; Female; Gemfibrozil; Glucuronides; Hepatocytes; Humans; Hypolipidemic Agents; Kinetics; Liver-Specific Organic Anion Transporter 1; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Pravastatin; Transport Vesicles; Xenopus laevis | 2007 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.
Topics: Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dyslipidemias; Gemfibrozil; HIV Infections; HIV Protease Inhibitors; Humans; Hypolipidemic Agents; Ireland; Pravastatin; Prevalence; Retrospective Studies | 2010 |
Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
Topics: Adolescent; Adult; Aged; Area Under Curve; Biological Transport; Cells, Cultured; Computer Simulation; Cyclosporine; Drug Interactions; Enzyme Inhibitors; Female; Gemfibrozil; Hepatocytes; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pravastatin; Rifampin; Young Adult | 2012 |
Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.
Topics: Area Under Curve; Cinnamates; Cyclosporine; Drug Interactions; Gemfibrozil; Humans; Indazoles; Liver-Specific Organic Anion Transporter 1; Models, Biological; Pravastatin; Rifampin; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2018 |
Pravastatin and Gemfibrozil Modulate Differently Hepatic and Colonic Mitochondrial Respiration in Tissue Homogenates from Healthy Rats.
Topics: Animals; Cell Respiration; Colon; Dose-Response Relationship, Drug; Gemfibrozil; Liver; Male; Mitochondria; Oxygen; Pravastatin; Rats; Rats, Wistar | 2019 |